Liver Disease Clinical Trials in Chicago

Showing 1-20 of 37 trials

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

NCT02968810

This phase II trial studies how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

CirrhosisHepatocellular Carcinoma

National Cancer Institute (NCI)52 participantsStarted Jun 2017

Los Angeles, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +2 more locations

NOT_YET_RECRUITINGPHASE22.2 miles

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

NCT03867487

This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

Non-Alcoholic Fatty Liver DiseaseNAFLDPediatric NAFLD

Justin Ryder40 participantsStarted May 2027

Chicago, Illinois, United States

RECRUITING2.2 miles

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

NCT05264051

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

Liver Diseases

University of Chicago1,200 participantsStarted Apr 2022

Chicago, Illinois, United States

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Liver Disease Trials in Other Cities

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

Longitudinal Study of Mitochondrial Hepatopathies

Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

Extracellular RNA Markers of Liver Disease and Cancer

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Phase 2b Study of GSK4532990 in Adults With NASH

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

Liver Cirrhosis Network Cohort Study

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis

Social & Contextual Impact on Children Undergoing Liver Transplantation

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Communication During Hospitalization About Resuscitation Trial

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

LITMUS Imaging Study

Other Conditions in Chicago